ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 1743

Kawasaki Disease: Is Intravenous Immunoglobulin Alone Adequate for the Child with Kawasaki Disease and Coronary Artery Lesions? A Retrospective Study of 65 Children with Kawasaki Disease from a Single North Indian Centre

Manjari Agarwal 1, Sumidha Mittal 1, Anju Singh 1, Neeraj Agarwal 2 and Sujata Sawhney1, 1Department of pediatric rheumatology, Sir Ganga Ram Hospital, New Delhi, India, New Delhi, India, 2Sir Gangaram Hospital, New delhi, India

Meeting: ACR/ARP Annual Meeting 2019

Keywords: Coronary Aneurysm and corticosteroids, Kawasaki disease

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: Pediatric Rheumatology – ePoster II: SLE, Juvenile Dermatomyositis, & Scleroderma

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Steroid use in Kawasaki disease (KD)is  controversial and has swung from contraindicated, to maybe &  now perhaps “should be given to all.”(1) Currently, standard practice is to use IVIg for all children with KD and add upfront steroids to IVIg only for those children who are at risk of non- response to IVIg , if such children can be identified. (2) There is data to support the use of  steroids at  2mg/kg/day as an add on to IVIg for the child who is at high risk of non response to the 1st IVIg (3)   At our center, over the last 18 years we have observed1. significant no. of children present with CALs & 2. These children often do not respond to  1st dose of IVIG. Thus, from 2017 we changed our practice & added steroids to IVIG as an upfront therapy to children presenting with CALs. We audited our practice & present the data on 65 children with KD.
Purpose:

  1. To study demographic & clinical profile of children with KD.
  2. To study response rate of IVIg
  3. To study the difference in response rate (if any ) for the child with KD & CALs who was given only IVIg ( pre 2017) or IVIg & steroids ( post 2017) at first presentation

Methods: All children diagnosed with KD from Jan13 to Apr19 were included. Clinical & demographic details were recorded on predesigned proformas. CALs were defined by z score (Boston) of more than 2 in any coronary artery. Response to IVIG was defined as no fever 36 hours post IVIG completion. Patients given IVIG alone got high dose aspirin, with steroids only low dose was given.SPSS 17.0 was used for analysis.

Results: 65 KD patients reviewed. Clinical & demographic details in Table 1. CALs were present in 31(47.6%) children at diagnosis. Boys had more CALs at onset than girls(p=0.059) IVIg was given to all. Steroids as first line were given to 13(20%): All had CALs. A second dose of IVIG was required by 13(20%).  Therapy detailed in Table 2.  IVIg alone had a poor response in those presenting with CALs. Addition of steroids to IVIG upfront was associated with significant increase in response in those with CALs(p=0.001) Details in table 3. No factors predicted the response to IVIG alone(age, day of diagnosis, C reactive protein). A higher z score predicted poor response to IVIG alone(p< 0.005), thus reiterating the fact that steroids are helpful in KD patients with CALs Kawasaki shock syndrome was seen in 2(3%) and macrophage activation syndrome in 1(1.5%),requiring high dose methylprednisolone(10-30mg/kg/day). At median follow up of 14 months(IQR 8-15), CALs normalized in 27(86%),5 persisted to have abnormal CALs. ( All  had giant aneurysms at presentation, Z scores >10). There was no mortality in this cohort.

Ref:

  1. Corticosteroids for the treatment of KD in children. Cochrane Review 2017.
  2. Diagnosis, Treatment, and Long-Term Management of KD. 2017.
  3. Efficacy of IVIG plus prednisolone for prevention of CALs in severe Kawasaki disease (RAISE study): Lancet 2012

Conclusion:

  1. 47% KD patients presented with CALs.
  2. KD with CALs have poor response to IVIG alone vs IVIG with upfront steroids (p=0.001)
  3. In addition to the well described scoring systems that predict a poor response to IVIG in the Japanese population, the presence of CALs and risk of non response to IVIG needs further study and replication in cohorts across the world.


table 1

Table 1: Clinical and demographic characteristics


table 2

Table 2: Details of therapy given per the echocardiographic findings


table 3

Table 3: Response to IVIg-alone without steroids- and factors predicting response to IVIg


Disclosure: M. Agarwal, None; S. Mittal, None; A. Singh, None; N. Agarwal, None; S. Sawhney, None.

To cite this abstract in AMA style:

Agarwal M, Mittal S, Singh A, Agarwal N, Sawhney S. Kawasaki Disease: Is Intravenous Immunoglobulin Alone Adequate for the Child with Kawasaki Disease and Coronary Artery Lesions? A Retrospective Study of 65 Children with Kawasaki Disease from a Single North Indian Centre [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/kawasaki-disease-is-intravenous-immunoglobulin-alone-adequate-for-the-child-with-kawasaki-disease-and-coronary-artery-lesions-a-retrospective-study-of-65-children-with-kawasaki-disease-from-a-single/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARP Annual Meeting 2019

ACR Meeting Abstracts - https://acrabstracts.org/abstract/kawasaki-disease-is-intravenous-immunoglobulin-alone-adequate-for-the-child-with-kawasaki-disease-and-coronary-artery-lesions-a-retrospective-study-of-65-children-with-kawasaki-disease-from-a-single/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology